BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 31, 2025
Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
Ocular, BioWorld Science RSS Feed RSS

Ocular

RNA-editing strategy to treat RHO-related retinitis pigmentosa

Nov. 7, 2024
Retinitis pigmentosa (RP) is the most common hereditary degenerative eye disease that leads to progressive vision loss, primarily caused by retinal degeneration.
Read More
Eye wireframe illustration
Ocular

QM-107, a novel therapeutic peptide for the treatment of neovascular eye diseases

Oct. 25, 2024
Syndecan-2 can inhibit angiogenesis through its interaction with the protein tyrosine phosphatase receptor CD148 (RTP type J).
Read More
DNA illustration
Ocular

AAV8-RK-hBBS10 increases retinal function and thickness in mouse model of Bardet-Biedl syndrome

Oct. 23, 2024
Mutations in the BBS10 gene are the second most common cause of Bardet-Biedl syndrome (BBS). Researchers from Meiragtx Ltd. aimed to optimize and identify an AAV vector carrying the human (h)BBS10 gene, obtaining sustained efficacy as well as good safety for clinical translation for the treatment of BBS.
Read More
Woman using eyedrops
Ocular

Grifols partners with BARDA to test ocular immunoglobulin for sulfur mustard-induced eye damage

Oct. 23, 2024
Grifols SA has entered into a partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to test investigational ocular surface immunoglobulin (OSIG) eye drops for their ability to treat ocular damage from sulfur mustard exposure.
Read More
Ocular

Shanghai Meiyue Biotech Development divulges new complement factor B inhibitors

Oct. 18, 2024
Shanghai Meiyue Biotech Development Co. Ltd. has synthesized spiro compounds acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of age-related macular degeneration, glomerulonephritis, atypical hemolytic uremic syndrome, membranous nephropathy, myasthenia gravis, paroxysmal nocturnal hemoglobinuria, diabetic retinopathy and rheumatoid arthritis, among others.
Read More
Man with eye disorder
Ocular

New study reveals druggable target for cataract treatment

Oct. 14, 2024
Protein homeostasis is disrupted in response to an uncontrolled stress condition, a hallmark of many diseases, such as cataracts. Lens protein accumulation and aggregates are a cause of cataract development.
Read More
Adult fly brain 3D reconstruction
Neurology/psychiatric

140,000 cells and 50M synapses make 1 adult fly brain

Oct. 2, 2024
By Mar de Miguel
A collaboration led by the Flywire Consortium and comprising hundreds of scientists has completed a whole map of the adult fruit fly brain after several decades of collaborative work. By using electron microscopy and three-dimensional reconstruction supported by AI tools, the researchers have revealed the neural wiring of the Drosophila melanogaster brain, a connectome of 140,000 neurons with 50 million synaptic connections. In the future, researchers could possibly use this map as an artificial in silico model to study the brain as a simulator through its connections, though a lot of work remains to be done for this.
Read More
Neurology/psychiatric

Anti-IL-6 receptor inhibition attenuates myelitis severity

Sep. 27, 2024
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune demyelinating disorder of the optic nerves and the spinal cord that is linked to the presence of anti-aquaporin (AQP4) autoantibodies. Satralizumab, a humanized anti-IL-6 receptor (IL-6R) antibody, has been approved for the treatment of NMOSD but the effects of IL-6R inhibition in myelitis severity have not been fully explored.
Read More
Ocular

EGR2 protects the eye from uveitis by impacting GDF15 signaling

Sep. 26, 2024
Uveitis is a disease involving the eye, affecting the iris, ciliary body, retina and their associated blood vessels, among others. The non-infectious type of uveitis is linked to immune-related factors and its pathogenesis remains poorly understood.
Read More
Illustration demonstrating structure of the human eye and organization of retinal cells
Ocular

Boehringer Ingelheim to advance SZN-413 for retinal diseases

Sep. 25, 2024
Surrozen Inc. has announced that Boehringer Ingelheim Pharma GmbH & Co. KG will further develop SZN-413 to advance the compound and prepare it for clinical testing. Boehringer decided to move forward with development based on the completion of the initial period of joint research under the companies’ strategic partnership for the research and development of SZN-413 for the treatment of retinal diseases.
Read More
Previous 1 2 … 5 6 7 8 9 10 11 12 13 … 360 361 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 30, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 30, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing